484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.174 1.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.168

Max

1.186

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	78M
Ankstesnė atidarymo kaina	0.14
Ankstesnė uždarymo kaina	1.174

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 17:04; UTC

Pagrindinės rinkos jėgos

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026-04-11 00:00; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Big Yachts, Big Bucks -- Barrons.com

2026-04-10 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026-04-10 21:01; UTC

Uždarbis

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026-04-10 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 20:31; UTC

Rinkos pokalbiai

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 19:15; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-10 19:15; UTC

Rinkos pokalbiai

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026-04-10 18:38; UTC

Rinkos pokalbiai

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026-04-10 18:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Finish With Weekly Gains -- Market Talk

2026-04-10 18:05; UTC

Rinkos pokalbiai

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026-04-10 17:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026-04-10 17:26; UTC

Uždarbis

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026-04-10 17:10; UTC

Rinkos pokalbiai

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026-04-10 17:00; UTC

Svarbiausios naujienos

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026-04-10 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-10 16:12; UTC

Uždarbis

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026-04-10 16:11; UTC

Uždarbis

Partners Group: Traditional Programs Contributed $3.3B

2026-04-10 16:10; UTC

Uždarbis

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026-04-10 16:10; UTC

Uždarbis

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026-04-10 16:10; UTC

Uždarbis

Partners Group 1Q New Client Demand $8.3B

2026-04-10 16:09; UTC

Uždarbis

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026-04-10 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Plenitude Completes Acquisition of Acea Energia

2026-04-10 15:38; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.